Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. This milestone advances the company's chemistry, manufacturing and controls (CMC) strategy as it progresses toward IND-enabling studies and planning for first-in-human clinical evaluation.
The program focuses on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates required for downstream manufacturing and formulation. The effort, conducted in collaboration with Dalton Pharma Services, aims to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness, and future clinical supply requirements.
This development is significant because ONC010 targets solid tumors through a patented technology that Onco-Innovations has secured an exclusive worldwide license to. By advancing the manufacturing process, the company is de-risking the drug's development pathway and positioning itself for regulatory milestones. A well-defined CMC strategy is essential for IND submissions and eventual clinical trials, as regulators require assurance of consistent drug quality and supply.
Onco-Innovations, a Canadian-based oncology company, is dedicated to cancer research and treatment through pioneering research and innovative solutions. The company's mission is to pursue the prevention and treatment of cancer, with a focus on solid tumors. For more information about Onco-Innovations, visit https://oncoinnovations.com/.
The full press release is available at https://nnw.fm/kfFWv. This announcement underscores the company's commitment to advancing its oncology pipeline and highlights the importance of manufacturing process development in bringing new cancer therapies to patients.
